Quick Answer
HALOZYME THERAPEUTICS, INC. reported Total Assets of $2.53 billion for fiscal year 2025.
HALOZYME THERAPEUTICS, INC. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $2.53B | +22.4% |
| 2024 | $2.06B | +19.1% |
| 2023 | $1.73B | -5.9% |
| 2022 | $1.84B | +66.7% |
| 2021 | $1.10B | +90.4% |
| 2020 | $579.92M | +2.5% |
| 2019 | $565.87M | +28.5% |
| 2018 | $440.25M | -15.3% |
| 2017 | $519.95M | +98.8% |
| 2016 | $261.51M | +43.9% |
| 2015 | $181.79M | +9.5% |
| 2014 | $165.98M | +63.1% |
| 2013 | $101.79M | -24.4% |
| 2012 | $134.73M | +104.9% |
| 2011 | $65.76M | -28.0% |
| 2010 | $91.35M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.22B | +4.9% | +8.1% |
| June 30, 2025 | $2.05B | +4.3% | -6.5% |
| March 31, 2025 | $2.20B | +19.3% | +6.4% |
| December 31, 2024 | $2.06B | +19.1% | -2.6% |
| September 30, 2024 | $2.12B | +11.9% | +7.5% |
| June 30, 2024 | $1.97B | +8.8% | +6.9% |
| March 31, 2024 | $1.84B | +8.4% | +6.2% |
| December 31, 2023 | $1.73B | -5.9% | -8.4% |
- HALOZYME THERAPEUTICS, INC. showed an increase of +22.4% in Total Assets compared to the prior fiscal year.
- Over the 2010–2025 period, HALOZYME THERAPEUTICS, INC.’s total assets has grown by 2664.6% (from $91.35 million to $2.53 billion).
- The most recent figure is from HALOZYME THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: